Medicure Inc. (MPH.V)
- Previous Close
0.8300 - Open
0.8700 - Bid 0.8700 x --
- Ask 1.0000 x --
- Day's Range
0.8700 - 0.8700 - 52 Week Range
0.6300 - 1.2600 - Volume
500 - Avg. Volume
1,858 - Market Cap (intraday)
9.08M - Beta (5Y Monthly) 0.69
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1000 - Earnings Date May 26, 2025 - May 30, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing Sodium Nitroprusside injection, and Generic ANDA 2 and 3 for acute cardiology; and TARDOCAL, to treat neurological indications. It offers products through retail and mail order pharmacies. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.
www.medicure.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: MPH.V
View MorePerformance Overview: MPH.V
Trailing total returns as of 5/12/2025, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MPH.V
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MPH.V
View MoreValuation Measures
Market Cap
8.66M
Enterprise Value
2.35M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.40
Price/Book (mrq)
0.42
Enterprise Value/Revenue
0.11
Enterprise Value/EBITDA
1.52
Financial Highlights
Profitability and Income Statement
Profit Margin
-4.74%
Return on Assets (ttm)
-5.93%
Return on Equity (ttm)
-5.11%
Revenue (ttm)
21.91M
Net Income Avi to Common (ttm)
-1.04M
Diluted EPS (ttm)
-0.1000
Balance Sheet and Cash Flow
Total Cash (mrq)
7.19M
Total Debt/Equity (mrq)
4.21%
Levered Free Cash Flow (ttm)
573.75k